All these studies suggest that specific targeting the downstream TGF-β/Smad3 signaling pathway by overexpression of Smad7, rather than blocking the general effect of TGF-β1 with neutralizing antibodies, may represent a specific and effective therapeutic strategy for kidney disease [46]. The gene discussed is SMAD7; the disease is kidney disorder.